Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R, Ibarrola-de Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B. Vera R, et al. Among authors: macarulla t. Rev Esp Patol. 2023 Jan-Mar;56(1):32-44. doi: 10.1016/j.patol.2022.06.004. Epub 2022 Aug 26. Rev Esp Patol. 2023. PMID: 36599598 Review.
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Rimini M, Fabregat-Franco C, Persano M, Burgio V, Bergamo F, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: macarulla t. Target Oncol. 2023 Jan;18(1):139-145. doi: 10.1007/s11523-022-00933-7. Epub 2023 Jan 23. Target Oncol. 2023. PMID: 36689074
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: macarulla t. Sci Rep. 2022 Nov 5;12(1):18775. doi: 10.1038/s41598-022-22543-z. Sci Rep. 2022. PMID: 36335135 Free PMC article.
Novel targets in gastric and esophageal cancer.
Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J. Valverde CM, et al. Among authors: macarulla t. Crit Rev Oncol Hematol. 2006 Aug;59(2):128-38. doi: 10.1016/j.critrevonc.2006.02.001. Epub 2006 Jul 10. Crit Rev Oncol Hematol. 2006. PMID: 16829119
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Tabernero J, et al. Among authors: macarulla t. J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. J Clin Oncol. 2008. PMID: 18332469 Clinical Trial.
168 results